肝移植は、様々な肝臓の病気において従来から行われている治療法です。肝臓は、体内の他の臓器とは異なり、再生または成長するユニークな能力を持っています。肝臓移植は、傷ついたり病気になったりした肝臓を健康なものに置き換えるものです。肝臓全体、または肝臓の一部分を移植することができます。移植後、免疫系は移植された肝臓を異物とみなし、対抗する可能性があります。そのため、患者さんは合併症を発症し、最終的には新しい臓器を拒絶する可能性があります。そのため、免疫抑制剤を同時に投与します。これらの免疫抑制剤は、体が様々な免疫反応によって異物と認識したり、攻撃したりするのを防ぐため、臓器拒否を防ぎ、移植を成功させることができるのです。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Transplant Rejection - Overview
Liver Transplant Rejection - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Transplant Rejection - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Transplant Rejection - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Astellas Pharma Inc
Dompe Farmaceutici SpA
Genexine Inc
ITB-Med AB
Junten Bio Co Ltd
Novartis AG
Pharmapraxis
Quell Therapeutics Ltd
Veloxis Pharmaceuticals AS
Liver Transplant Rejection - Drug Profiles
Cellular Immunotherapy for Liver Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellular Immunotherapy for Liver Transplantation - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Liver Transplantation - Drug Profile
Product Description
Mechanism Of Action
eculizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile
Product Description
Mechanism Of Action
GXP-10 - Drug Profile
Product Description
Mechanism Of Action
iscalimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
JB-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JB-102 - Drug Profile
Product Description
Mechanism Of Action
QEL-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
reparixin - Drug Profile
Product Description
Mechanism Of Action
History of Events
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
siplizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Liver Transplant Rejection and Kidney Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
tacrolimus - Drug Profile
Product Description
Mechanism Of Action
History of Events
tacrolimus ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
TR-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Liver Transplant Rejection - Dormant Projects
Liver Transplant Rejection - Discontinued Products
Liver Transplant Rejection - Product Development Milestones
Featured News & Press Releases
Jul 16, 2021: FDA approves new use of transplant drug based on real-world evidence
Jan 17, 2020: Astellas announces construction of new manufacturing facility for Active Pharmaceutical Ingredient of Prograf in Toyama Technology Center
Mar 18, 2019: Astellas launches PROGRAF Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients
Dec 04, 2009: Hikma signs new agreement for Advagraf with Astellas
Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Liver Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Liver Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, 2022
Liver Transplant Rejection - Pipeline by Astellas Pharma Inc, 2022
Liver Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, 2022
Liver Transplant Rejection - Pipeline by Genexine Inc, 2022
Liver Transplant Rejection - Pipeline by ITB-Med AB, 2022
Liver Transplant Rejection - Pipeline by Junten Bio Co Ltd, 2022
Liver Transplant Rejection - Pipeline by Novartis AG, 2022
Liver Transplant Rejection - Pipeline by Pharmapraxis, 2022
Liver Transplant Rejection - Pipeline by Quell Therapeutics Ltd, 2022
Liver Transplant Rejection - Pipeline by Veloxis Pharmaceuticals AS, 2022
Liver Transplant Rejection - Dormant Projects, 2022
Liver Transplant Rejection - Discontinued Products, 2022
List of Figures
Number of Products under Development for Liver Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
